Impact of Non-Adherence on Renal and Cardiovascular Outcomes in US Veterans

Elvira O. Gosmanova, Miklos Z. Molnar, Ahmed Alrifai, Jun L. Lu, Elani Streja, William Cushman, Kamyar Kalantar-Zadeh, Csaba Kovesdy

Research output: Contribution to journalArticle

8 Citations (Scopus)

Abstract

Background: Adherence is paramount in treating hypertension; however, no gold standard method is available for non-adherence screening, delineating high-risk patients. An International Classification of Diseases 9th Edition non-adherence diagnostic code (V15.81) has been available for decades; but, its utility is poorly studied. We examined the association between the V15.81 code assigned prior to the initiation of anti-hypertensive drugs (AHDs) and renal and cardiovascular outcomes. Methods: This was a historical prospective cohort study involving 312,489 newly treated hypertensive individuals (mean age 53.8 years, 90.9% males, 20.3% black, median follow-up 8.0 years). We used crude and Cox models adjusted for baseline socio-demographic characteristics, estimated glomerular filtration rate (eGFR), body mass index, blood pressure, comorbidities, and prospective AHD adherence (measured as proportion of days covered, PDC). Results: In the unadjusted analysis, the V15.81 code was associated with higher risks for faster eGFR decline (hazard ratio, HR 1.22, 95% CI 1.11-1.33), incident CKD (HR 1.17, 95% CI 1.09-1.27), end-stage renal disease (ESRD) (HR 2.53, 95% CI 1.72-3.72), incident coronary artery disease (CAD) (HR 1.26, 95% CI 1.15-1.38), and stroke (HR 1.55, 95% CI 1.38-1.73). In the adjusted model, the V15.81 code remained predictive of increased risk of CKD (HR 1.33, 95% CI 1.22-1.45), ESRD (HR 1.81, 95% CI 1.18-2.78), incident CAD (HR 1.26, 95% CI 1.14-1.40), and stroke (HR 1.46, 95% CI 1.29-1.65). Additional adjustment for PDC did not alter adverse associations between V15.81 code and studied outcomes. Conclusions: Assignment of V15.81 code prior to AHD therapy was associated with higher risks of renal and cardiovascular outcomes in incident hypertensive US veterans. Previous history of non-adherence is a poor prognostic marker in hypertensive individuals; therefore, patients with V15.81 code may require close monitoring. The observational nature of this study limits our ability to make firm recommendations for clinical practice.

Original languageEnglish (US)
Pages (from-to)151-157
Number of pages7
JournalAmerican Journal of Nephrology
Volume42
Issue number2
DOIs
StatePublished - Oct 16 2015

Fingerprint

Veterans
Antihypertensive Agents
Kidney
Glomerular Filtration Rate
Chronic Kidney Failure
Coronary Artery Disease
Stroke
International Classification of Diseases
Proportional Hazards Models
Observational Studies
Comorbidity
Body Mass Index
Cohort Studies
Demography
Prospective Studies
Blood Pressure
Hypertension
Drug Therapy

All Science Journal Classification (ASJC) codes

  • Nephrology

Cite this

Impact of Non-Adherence on Renal and Cardiovascular Outcomes in US Veterans. / Gosmanova, Elvira O.; Molnar, Miklos Z.; Alrifai, Ahmed; Lu, Jun L.; Streja, Elani; Cushman, William; Kalantar-Zadeh, Kamyar; Kovesdy, Csaba.

In: American Journal of Nephrology, Vol. 42, No. 2, 16.10.2015, p. 151-157.

Research output: Contribution to journalArticle

Gosmanova, EO, Molnar, MZ, Alrifai, A, Lu, JL, Streja, E, Cushman, W, Kalantar-Zadeh, K & Kovesdy, C 2015, 'Impact of Non-Adherence on Renal and Cardiovascular Outcomes in US Veterans', American Journal of Nephrology, vol. 42, no. 2, pp. 151-157. https://doi.org/10.1159/000440685
Gosmanova, Elvira O. ; Molnar, Miklos Z. ; Alrifai, Ahmed ; Lu, Jun L. ; Streja, Elani ; Cushman, William ; Kalantar-Zadeh, Kamyar ; Kovesdy, Csaba. / Impact of Non-Adherence on Renal and Cardiovascular Outcomes in US Veterans. In: American Journal of Nephrology. 2015 ; Vol. 42, No. 2. pp. 151-157.
@article{06f57b4897ce4877a85c728e81b651fd,
title = "Impact of Non-Adherence on Renal and Cardiovascular Outcomes in US Veterans",
abstract = "Background: Adherence is paramount in treating hypertension; however, no gold standard method is available for non-adherence screening, delineating high-risk patients. An International Classification of Diseases 9th Edition non-adherence diagnostic code (V15.81) has been available for decades; but, its utility is poorly studied. We examined the association between the V15.81 code assigned prior to the initiation of anti-hypertensive drugs (AHDs) and renal and cardiovascular outcomes. Methods: This was a historical prospective cohort study involving 312,489 newly treated hypertensive individuals (mean age 53.8 years, 90.9{\%} males, 20.3{\%} black, median follow-up 8.0 years). We used crude and Cox models adjusted for baseline socio-demographic characteristics, estimated glomerular filtration rate (eGFR), body mass index, blood pressure, comorbidities, and prospective AHD adherence (measured as proportion of days covered, PDC). Results: In the unadjusted analysis, the V15.81 code was associated with higher risks for faster eGFR decline (hazard ratio, HR 1.22, 95{\%} CI 1.11-1.33), incident CKD (HR 1.17, 95{\%} CI 1.09-1.27), end-stage renal disease (ESRD) (HR 2.53, 95{\%} CI 1.72-3.72), incident coronary artery disease (CAD) (HR 1.26, 95{\%} CI 1.15-1.38), and stroke (HR 1.55, 95{\%} CI 1.38-1.73). In the adjusted model, the V15.81 code remained predictive of increased risk of CKD (HR 1.33, 95{\%} CI 1.22-1.45), ESRD (HR 1.81, 95{\%} CI 1.18-2.78), incident CAD (HR 1.26, 95{\%} CI 1.14-1.40), and stroke (HR 1.46, 95{\%} CI 1.29-1.65). Additional adjustment for PDC did not alter adverse associations between V15.81 code and studied outcomes. Conclusions: Assignment of V15.81 code prior to AHD therapy was associated with higher risks of renal and cardiovascular outcomes in incident hypertensive US veterans. Previous history of non-adherence is a poor prognostic marker in hypertensive individuals; therefore, patients with V15.81 code may require close monitoring. The observational nature of this study limits our ability to make firm recommendations for clinical practice.",
author = "Gosmanova, {Elvira O.} and Molnar, {Miklos Z.} and Ahmed Alrifai and Lu, {Jun L.} and Elani Streja and William Cushman and Kamyar Kalantar-Zadeh and Csaba Kovesdy",
year = "2015",
month = "10",
day = "16",
doi = "10.1159/000440685",
language = "English (US)",
volume = "42",
pages = "151--157",
journal = "American Journal of Nephrology",
issn = "0250-8095",
publisher = "S. Karger AG",
number = "2",

}

TY - JOUR

T1 - Impact of Non-Adherence on Renal and Cardiovascular Outcomes in US Veterans

AU - Gosmanova, Elvira O.

AU - Molnar, Miklos Z.

AU - Alrifai, Ahmed

AU - Lu, Jun L.

AU - Streja, Elani

AU - Cushman, William

AU - Kalantar-Zadeh, Kamyar

AU - Kovesdy, Csaba

PY - 2015/10/16

Y1 - 2015/10/16

N2 - Background: Adherence is paramount in treating hypertension; however, no gold standard method is available for non-adherence screening, delineating high-risk patients. An International Classification of Diseases 9th Edition non-adherence diagnostic code (V15.81) has been available for decades; but, its utility is poorly studied. We examined the association between the V15.81 code assigned prior to the initiation of anti-hypertensive drugs (AHDs) and renal and cardiovascular outcomes. Methods: This was a historical prospective cohort study involving 312,489 newly treated hypertensive individuals (mean age 53.8 years, 90.9% males, 20.3% black, median follow-up 8.0 years). We used crude and Cox models adjusted for baseline socio-demographic characteristics, estimated glomerular filtration rate (eGFR), body mass index, blood pressure, comorbidities, and prospective AHD adherence (measured as proportion of days covered, PDC). Results: In the unadjusted analysis, the V15.81 code was associated with higher risks for faster eGFR decline (hazard ratio, HR 1.22, 95% CI 1.11-1.33), incident CKD (HR 1.17, 95% CI 1.09-1.27), end-stage renal disease (ESRD) (HR 2.53, 95% CI 1.72-3.72), incident coronary artery disease (CAD) (HR 1.26, 95% CI 1.15-1.38), and stroke (HR 1.55, 95% CI 1.38-1.73). In the adjusted model, the V15.81 code remained predictive of increased risk of CKD (HR 1.33, 95% CI 1.22-1.45), ESRD (HR 1.81, 95% CI 1.18-2.78), incident CAD (HR 1.26, 95% CI 1.14-1.40), and stroke (HR 1.46, 95% CI 1.29-1.65). Additional adjustment for PDC did not alter adverse associations between V15.81 code and studied outcomes. Conclusions: Assignment of V15.81 code prior to AHD therapy was associated with higher risks of renal and cardiovascular outcomes in incident hypertensive US veterans. Previous history of non-adherence is a poor prognostic marker in hypertensive individuals; therefore, patients with V15.81 code may require close monitoring. The observational nature of this study limits our ability to make firm recommendations for clinical practice.

AB - Background: Adherence is paramount in treating hypertension; however, no gold standard method is available for non-adherence screening, delineating high-risk patients. An International Classification of Diseases 9th Edition non-adherence diagnostic code (V15.81) has been available for decades; but, its utility is poorly studied. We examined the association between the V15.81 code assigned prior to the initiation of anti-hypertensive drugs (AHDs) and renal and cardiovascular outcomes. Methods: This was a historical prospective cohort study involving 312,489 newly treated hypertensive individuals (mean age 53.8 years, 90.9% males, 20.3% black, median follow-up 8.0 years). We used crude and Cox models adjusted for baseline socio-demographic characteristics, estimated glomerular filtration rate (eGFR), body mass index, blood pressure, comorbidities, and prospective AHD adherence (measured as proportion of days covered, PDC). Results: In the unadjusted analysis, the V15.81 code was associated with higher risks for faster eGFR decline (hazard ratio, HR 1.22, 95% CI 1.11-1.33), incident CKD (HR 1.17, 95% CI 1.09-1.27), end-stage renal disease (ESRD) (HR 2.53, 95% CI 1.72-3.72), incident coronary artery disease (CAD) (HR 1.26, 95% CI 1.15-1.38), and stroke (HR 1.55, 95% CI 1.38-1.73). In the adjusted model, the V15.81 code remained predictive of increased risk of CKD (HR 1.33, 95% CI 1.22-1.45), ESRD (HR 1.81, 95% CI 1.18-2.78), incident CAD (HR 1.26, 95% CI 1.14-1.40), and stroke (HR 1.46, 95% CI 1.29-1.65). Additional adjustment for PDC did not alter adverse associations between V15.81 code and studied outcomes. Conclusions: Assignment of V15.81 code prior to AHD therapy was associated with higher risks of renal and cardiovascular outcomes in incident hypertensive US veterans. Previous history of non-adherence is a poor prognostic marker in hypertensive individuals; therefore, patients with V15.81 code may require close monitoring. The observational nature of this study limits our ability to make firm recommendations for clinical practice.

UR - http://www.scopus.com/inward/record.url?scp=84942256070&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84942256070&partnerID=8YFLogxK

U2 - 10.1159/000440685

DO - 10.1159/000440685

M3 - Article

VL - 42

SP - 151

EP - 157

JO - American Journal of Nephrology

JF - American Journal of Nephrology

SN - 0250-8095

IS - 2

ER -